Latest News

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients, of whom 6 were T790M-positive and 5 were T790M-negative.

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Investigators randomly assigned 95 patients with ED-SCLC to receive pazopanib 800 mg daily or placebo.

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/carboplatin alone.

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

Researchers analyzed the resistance biopsies and plasma specimens of 119 patients with T790M-positive NSCLC treated with osimertinib.

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

Researchers enrolled 248 patients who progressed on pemetrexed-based chemotherapy with or without bevacizumab to receive second-line anetumab ravtansine or vinorelbine.

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

Researchers randomly assigned 89 patients with NSCLC to the SLND arm, in which patients underwent standard lung resection with SLND, or to the BML arm, in which patients received SLND plus contralateral mediastinal lymphadenectomy.

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs among patients treated with chemotherapy plus RT or chemotherapy alone.

SABR Improves Overall Survival Compared With CRT in NSCLC

SABR Improves Overall Survival Compared With CRT in NSCLC

The purpose of this study was to compare the effectiveness of SABR with CRT in prolonging time to local failure in this patient population.

Patients With High Out-of-pocket Costs Less Likely To Adhere to CML Therapy Plan

Patients With High Out-of-pocket Costs Less Likely To Adhere to CML Therapy Plan

A previous study noted a $30 median 30-day TKI supply copayment for privately insured patients. The median out-of-pocket cost was $452 for the same supply among patients included in this study.

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

Gilteritinib inhibits the FLT3 mutations observed in up to one-third of patients with AML, FLT3 internal tandem duplication, and the FLT3 tyrosine kinase domain.

Breast Cancer Treatment Intensity May Predict Likelihood of Leaving Employment

Breast Cancer Treatment Intensity May Predict Likelihood of Leaving Employment

The number of treatment options — coupled with the sometimes-overaggressive therapies used — suggests a need for integration of the potential financial effects of missed work into patient counseling after a breast cancer diagnosis.

Custirsen May Not Improve Survival in Castration-resistant Prostate Cancer

Custirsen May Not Improve Survival in Castration-resistant Prostate Cancer

Custirsen inhibits clusterin production, which is associated with chemotherapy resistance; previous study suggested that custirsen may improve progression-free survival in this setting.

FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC

FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC

The FDA grants Priority Review to medications with the potential to significantly improve outcomes or safety in the treatment, diagnosis, or prevention of serious conditions compared with available treatments.

Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC

Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC

Osimertinib was previously approved as a second-line therapy for patients with NSCLC who progress after treatment with an EGFR TKI because of the EGFR T790M resistance mutation.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters